A recent randomized trial, REC-CAGEFREE I, has shed light on the inefficacy of drug-coated balloon (DCB) angioplasty as an initial strategy for de novo coronary artery stenoses. The study revealed that DCB with rescue use of drug-eluting stents (DES) resulted in a significantly higher composite 24-month rate of cardiovascular death, target vessel myocardial infarction (MI),
0 Comments
Recently, a panel of Brazil’s federal supreme court justices made a unanimous decision to uphold orders suspending the use of Elon Musk’s social network, X, nationwide. This decision came after the court’s top justice, Alexandre de Moraes, issued controversial suspension orders late Friday. The court had warned Musk and X to appoint a legal representative
0 Comments
In a tragic turn of events following the Southport stabbings, childminder Lucy Connolly admitted to publishing written material to stir up racial hatred. Her post on social media called for mass deportation and burning down hotels filled with asylum seekers. This post was made on the same day as the knife attack in Southport, which
0 Comments
Investors in Asia-Pacific markets were faced with mixed results on Monday as they assessed the latest business activity numbers from China. China released its official purchasing managers’ index data for August, revealing a mixed bag of results. While the manufacturing PMI fell to a six-month low of 49.1, the non-manufacturing PMI showed an improvement to
0 Comments
In a heartwarming gesture of support and solidarity, Justin Baldoni, the star and director of ‘It Ends With Us’, recently penned a moving letter addressed to survivors of domestic violence. The letter, titled “Dear Survivor,” was shared on social media in collaboration with nonprofit organizations such as No More and Survivor Love Letter. Through his
0 Comments
A recent study conducted at Asan Medical Center in Seoul, South Korea, revealed some groundbreaking results regarding the use of edoxaban (Savaysa) monotherapy in patients with atrial fibrillation (Afib) and stable coronary artery disease (CAD). The EPIC-CAD trial compared the outcomes of patients on edoxaban monotherapy versus those on dual antithrombotic therapy and found that
0 Comments